Chitotriosidase: A New Inflammatory Marker in Diabetic Complications

Rosa, Michelino Di; Malaguarnera, Mariano

doi:10.1159/000443932

Cited by 32 publications

(18 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid accumulation promotes gene expression in macrophages, affecting the inflammatory process that occurs in atherogenesis [33] . Higher concentrations of chitotriosidase have been reported in the serum of patients with atherosclerosis than in controls (55-fold increase) as well as in sarcoidosis patients [29][30][31][32] . Chitinase 1 plays a role as inflammatory and profibrotic molecule in both diseases, suggesting that it may be a useful disease biomarker and indicator of atherosclerotic plaque formation, as well as in pulmonary granulomatous inflammation [34][35][36] .…”

Section: Chitotriosidase In Atherosclerosis and Sarcoidosismentioning

confidence: 97%

“…Atherosclerosis is associated with accumulation of lipids in artery walls after deposition of LDL cholesterol and fibrous matrix. In the early stage of this disease, monocytes differentiate into foam cells (lipidloaded macrophages generated by massive uptake of modified LDL) that take part in inflammatory responses and tissue remodeling in the arterial intima (vessel lumen narrowing and intimal thickening associated with increased risk of thrombosis) [29][30][31][32] . Lipid accumulation promotes gene expression in macrophages, affecting the inflammatory process that occurs in atherogenesis [33] .…”

Section: Chitotriosidase In Atherosclerosis and Sarcoidosismentioning

confidence: 99%

See 1 more Smart Citation

Increased Risk of Atherosclerosis in Patients with Sarcoidosis

Bargagli¹,

Rosi²,

Lavorini³

et al. 2017

Pathobiology

View full text Add to dashboard Cite

Sarcoidosis is a systemic granulomatous disease of unknown etiology. Recent studies demonstrated that its pathogenesis is related with enhanced oxidative stress (protein carbonylation and lipid peroxidation) and alterations in the circulating lipid profile. Alterations of lipid metabolism (including the reduction in high-density lipoprotein cholesterol levels and apolipoprotein A1 concentrations) induce plasma membrane, bronchial and lung capillary endothelial cell damage in sarcoidosis patients. Dyslipidemia is associated with increased oxidative stress, diminished overall antioxidative protection and increased risk for atherosclerosis. Very recently increased cardiovascular biomarkers (in particular alterations of lipoprotein A and d-dimer concentrations) were observed in sarcoidosis patients, mainly in those with a high risk of atherosclerosis. Chitotriosidase, a biomarker of sarcoidosis activity and macrophage activation, is increased in serum and bronchoalveolar lavage fluid of patients with sarcoidosis as well as in patients with atherosclerosis. Lipidomics and other recent methodologies allowed the discovery of proteins involved in lipid metabolism and sarcoidosis pathogenesis, such as serum amyloid A, a biomarker of sarcoidosis activity, involved in innate immune response, inflammation and apolipoprotein metabolism. In this review lipid metabolism alteration and atherosclerosis risk in sarcoidosis patients were discussed in order to contribute to this novel and interesting research topic.

show abstract

Section: Chitotriosidase In Atherosclerosis and Sarcoidosismentioning

confidence: 97%

Section: Chitotriosidase In Atherosclerosis and Sarcoidosismentioning

confidence: 99%

Increased Risk of Atherosclerosis in Patients with Sarcoidosis

Bargagli¹,

Rosi²,

Lavorini³

et al. 2017

Pathobiology

View full text Add to dashboard Cite

show abstract

“…It has been shown that CHIT1 levels increased significantly during the process of macrophage maturation towards the phenotypes of M1/M2 macrophages. While stimulation by TLR ligand/ IFN-γ leads to classical M1 activation, stimulation by IL-4/IL-1 leads to M2 activation [22]. It has been reported that IL-4 treatment induced the expression of mRNA CHIT1 and activated PPAR-γ [23,24].…”

Section: Discussionmentioning

confidence: 99%

Effect of PPAR-γ agonists on macrophage activation in type2 diabetes mellitus

Sözmen¹,

Karakaş²,

Topçugil³

et al. 2018

Ann Clin Anal Med

View full text Add to dashboard Cite

Effect of (PPAR-γ) agonists on macrophage activationEffect of PPAR-γ agonists on macrophage activation in type2 diabetes mellitus DOI: 10.4328 AbstractAim: Recently, it has been proposed that inflammation triggered by macrophages as the pathogenic mechanism linked to the development of obesity-related insulin resistance. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists which increase the insulin receptor sensitivity, might improve glycemic control by enhancing insulin sensitivity and ameliorate the impaired lipid profile. In this study, we assessed the effect of rosiglitazone (PPAR-γ agonist) on the insulin resistance and inflammatory markers. Material and Method: Thirty patients (11 men, 19 women) with type II diabetes mellitus (DM) were taken into the study. They were treated by rosiglitazone in a dose of 4mg/day as well as a diet for 12 weeks. Results: Rosiglitazone treatment significantly decreased HbA1c (p<0,01), IR-HOMA, hsCRP (p<0,01), triglyceride levels (p<0,05), CETP activity (p<0,01) and basal serum oxidation (TBARS levels, p<0,05). However, Chitotriosidase activity significantly increased after Rosiglitazone treatment (p<0,01). TNF, IL-6, sTNFR1, and sTNFR2 levels showed no statistically significant difference compared to their basal levels. Discussion: Rosiglitazone might treat diabetes by mediating glucose/lipid metabolism and preventing lipid oxidation in patients with DM. On the other hand, it has a dual role on inflammation; while it might induce macrophage activation suggesting its pro-inflammatory effect, it might also reduce the CRP levels by lowering gene expression suggesting its anti-inflammatory effect.

show abstract

“…Recent in-vivo and in-vitro studies suggest that ChT is involved at multiple points in different inflammatory and infectious diseases [10,[17][18][19][20][21] although the molecular mechanism of the ChT is far from being completely resolved in these conditions [10,22]. It was reported increased plasma ChT activity in neonates with fungal infection [10].…”

Section: Discussionmentioning

confidence: 99%

Chitotirosidase and prolidase in tinea pedis: A preliminary study

Doğan¹,

Hayta²

2017

Med-Science

View full text Add to dashboard Cite

Dermatophyte infections are superficial fungal infections. Tinea pedis is a dermatophyte infection of the feet and interdigital spaces. An evaluation was made of the chitotriosidase (ChT) concentrations, prolidase activity and the possible association between these biomarkers in tinea pedis. Study subjects were comprised of 42 patients with tinea pedis and 40 healthy subjects. Serum ChT concentrations and prolidase activity were determined in study population. Higher ChT concentrations were found in patients than controls (p < 0.001). We did not find any difference between groups in terms of prolidase activity (p = 0.162). We also did not found any correlation between ChT and prolidase activity. ChT seems to have roles during the inflammatory conditions in patients with tinea pedis. Whereas prolidase activity is not associated with the tinea pedis.

show abstract

Chitotriosidase: A New Inflammatory Marker in Diabetic Complications

Cited by 32 publications

References 60 publications

Increased Risk of Atherosclerosis in Patients with Sarcoidosis

Increased Risk of Atherosclerosis in Patients with Sarcoidosis

Effect of PPAR-γ agonists on macrophage activation in type2 diabetes mellitus

Chitotirosidase and prolidase in tinea pedis: A preliminary study

Contact Info

Product

Resources

About